Sumio Ohtsuki

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9400149/publications.pdf

Version: 2024-02-01

215 papers 13,012 citations

63 h-index 28297 105 g-index

227 all docs

227 docs citations

times ranked

227

12220 citing authors

#	Article	IF	CITATIONS
1	Acetylation of the influenza A virus polymerase subunit PA in the Nâ€terminal domain positively regulates its endonuclease activity. FEBS Journal, 2022, 289, 231-245.	4.7	9
2	Effect of Insulin Receptor-Knockdown on the Expression Levels of Blood–Brain Barrier Functional Proteins in Human Brain Microvascular Endothelial Cells. Pharmaceutical Research, 2022, 39, 1561-1574.	3.5	9
3	Knockdown of Podocalyxin Post-Transcriptionally Induces the Expression and Activity of ABCB1/MDR1 in Human Brain Microvascular Endothelial Cells. Journal of Pharmaceutical Sciences, 2022, , .	3.3	O
4	Targeted proteomics for cancer biomarker verification and validation. Cancer Biomarkers, 2022, 33, 427-436.	1.7	2
5	Diurnal Changes in Protein Expression at the Blood–Brain Barrier in Mice. Biological and Pharmaceutical Bulletin, 2022, 45, 751-756.	1.4	3
6	Water Droplet-in-Oil Digestion Method for Single-Cell Proteomics. Analytical Chemistry, 2022, 94, 10329-10336.	6.5	6
7	Nicotine promotes angiogenesis in mouse brain after intracerebral hemorrhage. Neuroscience Research, 2021, 170, 284-294.	1.9	5
8	Efficient isolation of brain capillary from a single frozen mouse brain for protein expression analysis. Journal of Cerebral Blood Flow and Metabolism, 2021, 41, 1026-1038.	4.3	14
9	Quantitative and targeted proteomics-based identification and validation of drug efficacy biomarkers. Drug Metabolism and Pharmacokinetics, 2021, 36, 100361.	2.2	18
10	Transient, Tunable Expression of NTCP and BSEP in MDCKII Cells for Kinetic Delineation of the Rate-Determining Process and Inhibitory Effects of Rifampicin in Hepatobiliary Transport of Taurocholate. Journal of Pharmaceutical Sciences, 2021, 110, 365-375.	3. 3	7
11	SHOC2 Is a Critical Modulator of Sensitivity to EGFR–TKIs in Non–Small Cell Lung Cancer Cells. Molecular Cancer Research, 2021, 19, 317-328.	3.4	12
12	Oral Coadministration of Zn-Insulin with <scp>d</scp> -Form Small Intestine-Permeable Cyclic Peptide Enhances Its Blood Glucose-Lowering Effect in Mice. Molecular Pharmaceutics, 2021, 18, 1593-1603.	4.6	11
13	Metformin ameliorates the severity of experimental Alport syndrome. Scientific Reports, 2021, 11, 7053.	3.3	18
14	Lysine Demethylase 5A Is Required for MYC-Driven Transcription in Multiple Myeloma. Blood Cancer Discovery, 2021, 2, 370-387.	5.0	19
15	In-vitro acetylation of SARS-CoV and SARS-CoV-2 nucleocapsid proteins by human PCAF and GCN5. Biochemical and Biophysical Research Communications, 2021, 557, 273-279.	2.1	15
16	Advances in sample preparation for membrane proteome quantification. Drug Discovery Today: Technologies, 2021, 39, 23-29.	4.0	5
17	Proteomics Analysis of Lymphatic Metastasis-Related Proteins Using Highly Metastatic Human Melanoma Cells Originated by Sequential <i>in Vivo</i> Implantation. Biological and Pharmaceutical Bulletin, 2021, 44, 1551-1556.	1.4	0
18	Oxidative stress-induced activation of Abl and Src kinases rapidly induces P-glycoprotein internalization via phosphorylation of caveolin-1 on tyrosine-14, decreasing cortisol efflux at the blood–brain barrier. Journal of Cerebral Blood Flow and Metabolism, 2020, 40, 420-436.	4.3	31

#	Article	IF	CITATIONS
19	Mass Spectrometry-Compatible Subcellular Fractionation for Proteomics. Journal of Proteome Research, 2020, 19, 75-84.	3.7	20
20	Targeted Proteomics-Based Quantitative Protein Atlas of Pannexin and Connexin Subtypes in Mouse and Human Tissues and Cancer Cell Lines. Journal of Pharmaceutical Sciences, 2020, 109, 1161-1168.	3.3	5
21	Lactose-appended \hat{l}^2 -cyclodextrin as an effective nanocarrier for brain delivery. Journal of Controlled Release, 2020, 328, 722-735.	9.9	17
22	The Multipotential of Leucine-Rich \hat{l} ±-2 Glycoprotein 1 as a Clinicopathological Biomarker of Glioblastoma. Journal of Neuropathology and Experimental Neurology, 2020, 79, 873-879.	1.7	9
23	Evaluation of cytochrome P450-based drug metabolism in hemorrhagic shock rats that were transfused with native and an artificial red blood cell preparation, Hemoglobin-vesicles. Drug Metabolism and Pharmacokinetics, 2020, 35, 417-424.	2.2	2
24	Proteomic Evaluation of Plasma Membrane Fraction Prepared from a Mouse Liver and Kidney Using a Bead Homogenizer: Enrichment of Drug-Related Transporter Proteins. Molecular Pharmaceutics, 2020, 17, 4101-4113.	4.6	5
25	Gelsolin inhibits malignant phenotype of glioblastoma and is regulated by miRâ€654â€5p and miRâ€450bâ€5p. Cancer Science, 2020, 111, 2413-2422.	3.9	20
26	Cyclocreatine Transport by SLC6A8, the Creatine Transporter, in HEK293 Cells, a Human Blood-Brain Barrier Model Cell, and CCDSs Patient-Derived Fibroblasts. Pharmaceutical Research, 2020, 37, 61.	3.5	7
27	Novel cyclic peptides facilitating transcellular blood-brain barrier transport of macromolecules in vitro and in vivo. Journal of Controlled Release, 2020, 321, 744-755.	9.9	30
28	Identification of Cell-Surface Proteins Endocytosed by Human Brain Microvascular Endothelial Cells In Vitro. Pharmaceutics, 2020, 12, 579.	4.5	12
29	Laminin Subunit Alpha-4 and Osteopontin Are Glioblastoma-Selective Secreted Proteins That Are Increased in the Cerebrospinal Fluid of Glioblastoma Patients. Journal of Proteome Research, 2020, 19, 3542-3553.	3.7	8
30	Assessing cytochrome P450-based drug-drug interactions with hemoglobin-vesicles, an artificial red blood cell preparation, in healthy rats. Drug Metabolism and Pharmacokinetics, 2020, 35, 425-431.	2.2	4
31	Convenient method of producing cyclic single-chain Fv antibodies by split-intein-mediated protein ligation and chaperone co-expression. Journal of Biochemistry, 2020, 168, 257-263.	1.7	3
32	Matrix mechanotransduction mediated by thrombospondin-1/integrin/YAP in the vascular remodeling. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 9896-9905.	7.1	90
33	Effects of differences in pre-analytical processing on blood protein profiles determined with SWATH-MS. Journal of Proteomics, 2020, 223, 103824.	2.4	5
34	Abstract 3081: SHOC2 is a critical modulator of the sensitivity to EGFR-TKI in non-small cell lung cancer cells. , 2020, , .		1
35	Involvement of Claudin-11 in Disruption of Blood-Brain, -Spinal Cord, and -Arachnoid Barriers in Multiple Sclerosis. Molecular Neurobiology, 2019, 56, 2039-2056.	4.0	66
36	Changes of Blood-Brain Barrier and Brain Parenchymal Protein Expression Levels of Mice under Different Insulin-Resistance Conditions Induced by High-Fat Diet. Pharmaceutical Research, 2019, 36, 141.	3.5	29

3

#	Article	IF	CITATIONS
37	Development of a lipoplex-type mRNA carrier composed of an ionizable lipid with a vitamin E scaffold and the KALA peptide for use as an ex vivo dendritic cell-based cancer vaccine. Journal of Controlled Release, 2019, 310, 36-46.	9.9	61
38	Cyclization of Single-Chain Fv Antibodies Markedly Suppressed Their Characteristic Aggregation Mediated by Inter-Chain VH-VL Interactions. Molecules, 2019, 24, 2620.	3.8	20
39	Leucine-Rich Alpha-2-Glycoprotein 1 in Serum Is a Possible Biomarker to Predict Response to Preoperative Chemoradiotherapy for Esophageal Cancer. Biological and Pharmaceutical Bulletin, 2019, 42, 1766-1771.	1.4	13
40	Proteomic analysis of small intestinal epithelial cells in antibiotic-treated mice: Changes in drug transporters and metabolizing enzymes. Drug Metabolism and Pharmacokinetics, 2019, 34, 159-162.	2.2	8
41	Tandem Mass Spectrometry Imaging Reveals Distinct Accumulation Patterns of Steroid Structural Isomers in Human Adrenal Glands. Analytical Chemistry, 2019, 91, 8918-8925.	6.5	48
42	Elucidation of Permeation Molecular Mechanism of New Small Intestine Permeable Peptides. Impact, 2019, 2019, 73-75.	0.1	0
43	Large-Scale Quantitative Comparison of Plasma Transmembrane Proteins between Two Human Blood–Brain Barrier Model Cell Lines, hCMEC/D3 and HBMEC/cil̂². Molecular Pharmaceutics, 2019, 16, 2162-2171.	4.6	18
44	CBMT-18. THE ROLE OF BIOMARKER CANDIDATE GELSOLIN AND ITS MICRORNAS IN GLIOBLASTOMA. Neuro-Oncology, 2019, 21, vi36-vi37.	1.2	0
45	Urate Transport <i>via</i> Paracellular Route across Epithelial Cells. Biological and Pharmaceutical Bulletin, 2019, 42, 43-49.	1.4	1
46	Knockdown of Orphan Transporter SLC22A18 Impairs Lipid Metabolism and Increases Invasiveness of HepG2 Cells. Pharmaceutical Research, 2019, 36, 39.	3.5	9
47	Identification of a Specific Translational Machinery via TCTP–EF1A2 Interaction Regulating NF1-associated Tumor Growth by Affinity Purification and Data-independent Mass Spectrometry Acquisition (AP-DIA)*. Molecular and Cellular Proteomics, 2019, 18, 245-262.	3.8	13
48	Comparison of venous and fingertip plasma using non-targeted proteomics and metabolomics. Talanta, 2019, 192, 182-188.	5. 5	8
49	Molecular characterization of urate transport via paracellular route Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2019, 92, 1-P-111.	0.0	O
50	Effect of changes in intestinal flora induced by short-term antibiotics administration on the pharmacokinetics of drugs, and glucose and lipid metabolism. Drug Metabolism and Pharmacokinetics, 2018, 33, S56.	2.2	1
51	Gene therapy for <i>Glut1</i> àêdeficient mouse using an adenoâ€associated virus vector with the human intrinsic GLUT1 promoter. Journal of Gene Medicine, 2018, 20, e3013.	2.8	15
52	Reduction in hepatic secondary bile acids caused by short-term antibiotic-induced dysbiosis decreases mouse serum glucose and triglyceride levels. Scientific Reports, 2018, 8, 1253.	3.3	73
53	ATP-Binding Cassette Transporter A Subfamily 8 Is a Sinusoidal Efflux Transporter for Cholesterol and Taurocholate in Mouse and Human Liver. Molecular Pharmaceutics, 2018, 15, 343-355.	4.6	23
54	High Expression of UGT1A1/1A6 in Monkey Small Intestine: Comparison of Protein Expression Levels of Cytochromes P450, UDP-Glucuronosyltransferases, and Transporters in Small Intestine of Cynomolgus Monkey and Human. Molecular Pharmaceutics, 2018, 15, 127-140.	4.6	32

#	Article	IF	CITATIONS
55	Involvement of an Orphan Transporter, SLC22A18, in Cell Growth and Drug Resistance of Human Breast Cancer MCF7 Cells. Journal of Pharmaceutical Sciences, 2018, 107, 3163-3170.	3.3	12
56	Influenza virus replication raises the temperature of cells. Virus Research, 2018, 257, 94-101.	2.2	10
57	SIRT7 has a critical role in bone formation by regulating lysine acylation of SP7/Osterix. Nature Communications, 2018, 9, 2833.	12.8	65
58	Characterization of P-Glycoprotein Humanized Mice Generated by Chromosome Engineering Technology: Its Utility for Prediction of Drug Distribution to the Brain in Humans. Drug Metabolism and Disposition, 2018, 46, 1756-1766.	3.3	21
59	Identification of blood biomarkers in glioblastoma by SWATH mass spectrometry and quantitative targeted absolute proteomics. PLoS ONE, 2018, 13, e0193799.	2.5	87
60	Gene therapy for a mouse model of glucose transporter-1 deficiency syndrome. Molecular Genetics and Metabolism Reports, 2017, 10, 67-74.	1.1	12
61	Actin filamentâ€associated protein 1 (AFAPâ€1) is a key mediator in inflammatory signalingâ€induced rapid attenuation of intrinsic Pâ€gp function in human brain capillary endothelial cells. Journal of Neurochemistry, 2017, 141, 247-262.	3.9	20
62	Downregulation of GNA13-ERK network in prefrontal cortex of schizophrenia brain identified by combined focused and targeted quantitative proteomics. Journal of Proteomics, 2017, 158, 31-42.	2.4	40
63	All-trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kinase. European Journal of Pharmaceutical Sciences, 2017, 103, 116-121.	4.0	13
64	Application of Quantitative Targeted Absolute Proteomics to Profile Protein Expression Changes of Hepatic Transporters and Metabolizing Enzymes During Cholic Acid-Promoted Liver Regeneration. Journal of Pharmaceutical Sciences, 2017, 106, 2499-2508.	3.3	7
65	Regulation of Tight-Junction Integrity by Insulin in an InÂVitro Model of Human Blood–Brain Barrier. Journal of Pharmaceutical Sciences, 2017, 106, 2599-2605.	3.3	31
66	Scrambled Internal Standard Method for High-Throughput Protein Quantification by Matrix-Assisted Laser Desorption Ionization Tandem Mass Spectrometry. Journal of Proteome Research, 2017, 16, 1556-1565.	3.7	5
67	The bloodâ€brain barrier fatty acid transport protein 1 (<scp>FATP</scp> 1/ <scp>SLC</scp> 27A1) supplies docosahexaenoic acid to the brain, and insulin facilitates transport. Journal of Neurochemistry, 2017, 141, 400-412.	3.9	45
68	A simplified and sensitive method to identify Alzheimer's disease biomarker candidates using patient-derived induced pluripotent stem cells (iPSCs). Journal of Biochemistry, 2017, 162, 391-394.	1.7	15
69	Combining Genomics To Identify the Pathways of Post-Transcriptional Nongenotoxic Signaling and Energy Homeostasis in Livers of Rats Treated with the Pregnane X Receptor Agonist, Pregnenolone Carbonitrile. Journal of Proteome Research, 2017, 16, 3634-3645.	3.7	4
70	Multi-laboratory assessment of reproducibility, qualitative and quantitative performance of SWATH-mass spectrometry. Nature Communications, 2017, 8, 291.	12.8	423
71	Identification of cyclic peptides for facilitation of transcellular transport of phages across intestinal epithelium in vitro and in vivo. Journal of Controlled Release, 2017, 262, 232-238.	9.9	22
72	Abnormal <i>N</i> -Glycosylation of a Novel Missense Creatine Transporter Mutant, G561R, Associated with Cerebral Creatine Deficiency Syndromes Alters Transporter Activity and Localization. Biological and Pharmaceutical Bulletin, 2017, 40, 49-55.	1.4	11

#	Article	IF	CITATIONS
73	Largeâ€scale multiplex absolute protein quantification of drugâ€metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATHâ€MS: Comparison with MRM/SRM and HRâ€MRM/PRM. Proteomics, 2016, 16, 2106-2117.	2.2	109
74	Quantitative Targeted Absolute Proteomics for 28 Transporters in Brush-Border and Basolateral Membrane Fractions of Rat Kidney. Journal of Pharmaceutical Sciences, 2016, 105, 1011-1016.	3.3	19
75	Front cover: Large-scale multiplex absolute protein quantification of drug-metabolizing enzymes and transporters in human intestine, liver, and kidney microsomes by SWATH-MS: Comparison with MRM/SRM and HR-MRM/PRM. Proteomics, 2016, 16, NA-NA.	2.2	0
76	Effect of Intestinal Flora on Protein Expression of Drug-Metabolizing Enzymes and Transporters in the Liver and Kidney of Germ-Free and Antibiotics-Treated Mice. Molecular Pharmaceutics, 2016, 13, 2691-2701.	4.6	80
77	Quantitative Targeted Absolute Proteomics of Transporters and Pharmacoproteomics-Based Reconstruction of P-Glycoprotein Function in Mouse Small Intestine. Molecular Pharmaceutics, 2016, 13, 2443-2456.	4.6	17
78	Identification of IGFBP2 and IGFBP3 As Compensatory Biomarkers for CA19-9 in Early-Stage Pancreatic Cancer Using a Combination of Antibody-Based and LC-MS/MS-Based Proteomics. PLoS ONE, 2016, 11, e0161009.	2.5	76
79	Quantitative Determination of Luminal and Abluminal Membrane Distributions of Transporters in Porcine Brain Capillaries by Plasma Membrane Fractionation and Quantitative Targeted Proteomics. Journal of Pharmaceutical Sciences, 2015, 104, 3060-3068.	3.3	69
80	Major involvement of Na ⁺ â€dependent multivitamin transporter (SLC5A6/SMVT) in uptake of biotin and pantothenic acid by human brain capillary endothelial cells. Journal of Neurochemistry, 2015, 134, 97-112.	3.9	81
81	Contribution of Pannexin 1 and Connexin 43 Hemichannels to Extracellular Calcium–Dependent Transport Dynamics in Human Blood-Brain Barrier Endothelial Cells. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 192-200.	2.5	39
82	Design and synthesis of a novel pre-column derivatization reagent with a 6-methoxy-4-quinolone moiety for fluorescence and tandem mass spectrometric detection and its application to chiral amino acid analysis. Journal of Pharmaceutical and Biomedical Analysis, 2015, 116, 71-79.	2.8	11
83	Quantitative Targeted Proteomics of Pancreatic Cancer: Deoxycytidine Kinase Protein Level Correlates to Progression-Free Survival of Patients Receiving Gemcitabine Treatment. Molecular Pharmaceutics, 2015, 12, 3282-3291.	4.6	38
84	Quantitative targeted absolute proteomics for 28 human transporters in plasma membrane of Caco-2 cell monolayer cultured for 2, 3, and 4Âweeks. Drug Metabolism and Pharmacokinetics, 2015, 30, 205-208.	2.2	38
85	Blood-Brain Barrier Pharmacoproteomics-Based Reconstruction of the In Vivo Brain Distribution of P-Glycoprotein Substrates in Cynomolgus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2014, 350, 578-588.	2.5	52
86	CS-25 * MOLECULAR SUBCLASSIFICATION OF GLIOBLASTOMA BASED ON THE ABSOLUTE QUANTITATIVE PROTEOMICS. Neuro-Oncology, 2014, 16, ν 56- ν 56.	1.2	0
87	Pharmacoproteomics-Based Reconstruction of In Vivo P-Glycoprotein Function at Blood-Brain Barrier and Brain Distribution of Substrate Verapamil in Pentylenetetrazole-Kindled Epilepsy, Spontaneous Epilepsy, and Phenytoin Treatment Models. Drug Metabolism and Disposition, 2014, 42, 1719-1726.	3.3	29
88	Quantitative targeted proteomics for understanding the blood–brain barrier: towards pharmacoproteomics. Expert Review of Proteomics, 2014, 11, 303-313.	3.0	38
89	Validation of uPA/SCID Mouse with Humanized Liver as a Human Liver Model: Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases by LC-MS/MS. Drug Metabolism and Disposition, 2014, 42, 1039-1043.	3.3	37
90	Recent Progress in Blood–Brain Barrier and Blood–CSF Barrier Transport Research: Pharmaceutical Relevance for Drug Delivery to the Brain. AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 23-62.	0.6	11

#	Article	IF	Citations
91	Blood–Brain Barrier (BBB) Pharmacoproteomics: A New Research Field Opened Up by Quantitative Targeted Absolute Proteomics (QTAP). AAPS Advances in the Pharmaceutical Sciences Series, 2014, , 63-100.	0.6	2
92	A study protocol for quantitative targeted absolute proteomics (QTAP) by LC-MS/MS: application for inter-strain differences in protein expression levels of transporters, receptors, claudin-5, and marker proteins at the blood–brain barrier in ddY, FVB, and C57BL/6J mice. Fluids and Barriers of the CNS, 2013, 10, 21.	5.0	185
93	Contributions of Degradation and Brain-to-blood Elimination Across the Blood—Brain Barrier to Cerebral Clearance of Human Amyloid-β Peptide(1-40) in Mouse Brain. Journal of Cerebral Blood Flow and Metabolism, 2013, 33, 1770-1777.	4.3	16
94	Identification of Transporters Associated with Etoposide Sensitivity of Stomach Cancer Cell Lines and Methotrexate Sensitivity of Breast Cancer Cell Lines by Quantitative Targeted Absolute Proteomics. Molecular Pharmacology, 2013, 83, 490-500.	2.3	23
95	Quantitative expression of human drug transporter proteins in lung tissues: Analysis of regional, gender, and interindividual differences by liquid chromatography–tandem mass spectrometry. Journal of Pharmaceutical Sciences, 2013, 102, 3395-3406.	3.3	72
96	Quantitative Targeted Absolute Proteomic Analysis of Transporters, Receptors and Junction Proteins for Validation of Human Cerebral Microvascular Endothelial Cell Line hCMEC/D3 as a Human Blood–Brain Barrier Model. Molecular Pharmaceutics, 2013, 10, 289-296.	4.6	190
97	Quantitative Targeted Absolute Proteomics-Based Large-Scale Quantification of Proline-Hydroxylated α-Fibrinogen in Plasma for Pancreatic Cancer Diagnosis. Journal of Proteome Research, 2013, 12, 753-762.	3.7	31
98	Quantitative Atlas of Blood–Brain Barrier Transporters, Receptors, and Tight Junction Proteins in Rats and Common Marmoset. Journal of Pharmaceutical Sciences, 2013, 102, 3343-3355.	3.3	198
99	Establishment and characterization of spinal cord microvascular endothelial cell lines. Clinical and Experimental Neuroimmunology, 2013, 4, 326-338.	1.0	20
100	Trans-chromosomic mice containing a human CYP3A cluster for prediction of xenobiotic metabolism in humans. Human Molecular Genetics, 2013, 22, 578-592.	2.9	68
101	Involvement of Insulin-Degrading Enzyme in Insulin- and Atrial Natriuretic Peptide-Sensitive Internalization of Amyloid-1² Peptide in Mouse Brain Capillary Endothelial Cells. Journal of Alzheimer's Disease, 2013, 38, 185-200.	2.6	29
102	Simultaneous Absolute Protein Quantification of Transporters, Cytochromes P450, and UDP-Glucuronosyltransferases as a Novel Approach for the Characterization of Individual Human Liver: Comparison with mRNA Levels and Activities. Drug Metabolism and Disposition, 2012, 40, 83-92.	3.3	373
103	Absolute Quantification and Differential Expression of Drug Transporters, Cytochrome P450 Enzymes, and UDP-Glucuronosyltransferases in Cultured Primary Human Hepatocytes. Drug Metabolism and Disposition, 2012, 40, 93-103.	3.3	121
104	Attenuation of Phosphorylation by Deoxycytidine Kinase is Key to Acquired Gemcitabine Resistance in a Pancreatic Cancer Cell Line: Targeted Proteomic and Metabolomic Analyses in PK9 Cells. Pharmaceutical Research, 2012, 29, 2006-2016.	3.5	23
105	Recurrent anaplastic meningioma treated by sunitinib based on results from quantitative proteomics. Neuropathology and Applied Neurobiology, 2012, 38, 105-110.	3.2	11
106	Transcriptomic and Quantitative Proteomic Analysis of Transporters and Drug Metabolizing Enzymes in Freshly Isolated Human Brain Microvessels. Molecular Pharmaceutics, 2011, 8, 1332-1341.	4.6	324
107	Blood-Brain Barrier (BBB) Pharmacoproteomics: Reconstruction of In Vivo Brain Distribution of 11 P-Glycoprotein Substrates Based on the BBB Transporter Protein Concentration, In Vitro Intrinsic Transport Activity, and Unbound Fraction in Plasma and Brain in Mice. Journal of Pharmacology and Experimental Therapeutics. 2011. 339. 579-588.	2.5	116
108	Molecular-weight-dependent, Anionic-substrate-preferential Transport of \hat{l}^2 -Lactam Antibiotics via Multidrug Resistance-associated Protein 4. Drug Metabolism and Pharmacokinetics, 2011, 26, 602-611.	2.2	29

#	Article	lF	Citations
109	Quantitative targeted absolute proteomics of human blood–brain barrier transporters and receptors. Journal of Neurochemistry, 2011, 117, 333-345.	3.9	683
110	Amyloidâ€Î² peptide(1â€40) elimination from cerebrospinal fluid involves lowâ€density lipoprotein receptorâ€related protein 1 at the bloodâ€cerebrospinal fluid barrier. Journal of Neurochemistry, 2011, 118, 407-415.	3.9	46
111	Atrial Natriuretic Peptide is Eliminated from the Brain by Natriuretic Peptide Receptor-C-Mediated Brain-to-Blood Efflux Transport at the Blood—Brain Barrier. Journal of Cerebral Blood Flow and Metabolism, 2011, 31, 457-466.	4.3	18
112	Attenuation of prostaglandin E2 elimination across the mouse blood-brain barrier in lipopolysaccharide-induced inflammation and additive inhibitory effect of cefmetazole. Fluids and Barriers of the CNS, 2011, 8, 24.	5.0	33
113	$1\hat{l}\pm,25$ -Dihydroxyvitamin D3 enhances cerebral clearance of human amyloid- \hat{l}^2 peptide(1-40) from mouse brain across the blood-brain barrier. Fluids and Barriers of the CNS, 2011, 8, 20.	5.0	85
114	Simultaneous Absolute Quantification of 11 Cytochrome P450 Isoforms in Human Liver Microsomes by Liquid Chromatography Tandem Mass Spectrometry with In Silico Target Peptide Selection. Journal of Pharmaceutical Sciences, 2011, 100, 341-352.	3.3	150
115	Quantitative Membrane Protein Expression at the Blood–Brain Barrier of Adult and Younger Cynomolgus Monkeys. Journal of Pharmaceutical Sciences, 2011, 100, 3939-3950.	3.3	197
116	Reliability and Robustness of Simultaneous Absolute Quantification of Drug Transporters, Cytochrome P450 Enzymes, and Udp-Glucuronosyltransferases in Human Liver Tissue by Multiplexed MRM/Selected Reaction Monitoring Mode Tandem Mass Spectrometry with Nano-Liquid Chromatography. Journal of Pharmaceutical Sciences, 2011, 100, 4037-4043.	3.3	55
117	Functional characterization of Rat Plasma Membrane Monoamine Transporter in the Blood–Brain and Blood–Cerebrospinal Fluid Barriers. Journal of Pharmaceutical Sciences, 2011, 100, 3924-3938.	3.3	41
118	Quantitative Targeted Absolute Proteomics-Based Adme Research as A New Path to Drug Discovery and Development: Methodology, Advantages, Strategy, and Prospects. Journal of Pharmaceutical Sciences, 2011, 100, 3547-3559.	3.3	125
119	6-Mercaptopurine Transport by Equilibrative Nucleoside Transporters in Conditionally Immortalized Rat Syncytiotrophoblast Cell Lines TR-TBTs. Journal of Pharmaceutical Sciences, 2011, 100, 3773-3782.	3.3	15
120	Peripheral nerve pericytes modify the blood–nerve barrier function and tight junctional molecules through the secretion of various soluble factors. Journal of Cellular Physiology, 2011, 226, 255-266.	4.1	101
121	Expression of ABC-type transport proteins in human platelets. Pharmacogenetics and Genomics, 2010, 20, 396-400.	1.5	32
122	Reduction of L-Type Amino Acid Transporter 1 mRNA Expression in Brain Capillaries in a Mouse Model of Parkinson's Disease. Biological and Pharmaceutical Bulletin, 2010, 33, 1250-1252.	1.4	27
123	Establishment of a new conditionally immortalized human brain microvascular endothelial cell line retaining an in vivo blood–brain barrier function. Journal of Cellular Physiology, 2010, 225, 519-528.	4.1	109
124	Lack of brainâ€toâ€blood efflux transport activity of lowâ€density lipoprotein receptorâ€related proteinâ€1 (LRPâ€1) for amyloidâ€Î² peptide(1–40) in mouse: involvement of an LRPâ€1â€independent pathway. Journal of Neurochemistry, 2010, 113, 1356-1363.	of 3.9	39
125	Is P-glycoprotein Involved in Amyloid-β Elimination Across the Blood–Brain Barrier in Alzheimer's Disease?. Clinical Pharmacology and Therapeutics, 2010, 88, 443-445.	4.7	20
126	Involvement of Multidrug Resistance-Associated Protein 4 in Efflux Transport of Prostaglandin E ₂ across Mouse Blood-Brain Barrier and Its Inhibition by Intravenous Administration of Cephalosporins. Journal of Pharmacology and Experimental Therapeutics, 2010, 333, 912-919.	2.5	33

#	Article	IF	CITATIONS
127	Depletion of Vitamin E Increases Amyloid \hat{l}^2 Accumulation by Decreasing Its Clearances from Brain and Blood in a Mouse Model of Alzheimer Disease. Journal of Biological Chemistry, 2009, 284, 33400-33408.	3.4	91
128	Human Platelets Express Organic Anion-Transporting Peptide 2B1, an Uptake Transporter for Atorvastatin. Drug Metabolism and Disposition, 2009, 37, 1129-1137.	3.3	59
129	$\hat{Al^2}$ Immunotherapy: Intracerebral Sequestration of $\hat{Al^2}$ by an Anti- $\hat{Al^2}$ Monoclonal Antibody 266 with High Affinity to Soluble $\hat{Al^2}$. Journal of Neuroscience, 2009, 29, 11393-11398.	3.6	103
130	Beneficial Effects of Estrogen in a Mouse Model of Cerebrovascular Insufficiency. PLoS ONE, 2009, 4, e5159.	2.5	34
131	mRNA expression levels of tight junction protein genes in mouse brain capillary endothelial cells highly purified by magnetic cell sorting. Journal of Neurochemistry, 2008, 104, 147-154.	3.9	115
132	Quantitative Atlas of Membrane Transporter Proteins: Development and Application of a Highly Sensitive Simultaneous LC/MS/MS Method Combined with Novel In-silico Peptide Selection Criteria. Pharmaceutical Research, 2008, 25, 1469-1483.	3.5	453
133	Peripheral Nerve pericytes originating from the blood–nerve barrier expresses tight junctional molecules and transporters as barrierâ€forming cells. Journal of Cellular Physiology, 2008, 217, 388-399.	4.1	99
134	Expression of nuclear receptor mRNA and liver X receptor-mediated regulation of ABC transporter A1 at rat blood–brain barrier. Neurochemistry International, 2008, 52, 669-674.	3.8	43
135	ATP-binding cassette transporter A1 (ABCA1) deficiency does not attenuate the brain-to-blood efflux transport of human amyloid-β peptide (1–40) at the blood–brain barrier. Neurochemistry International, 2008, 52, 956-961.	3.8	50
136	The Low Density Lipoprotein Receptor-related Protein 1 Mediates Uptake of Amyloid \hat{l}^2 Peptides in an in Vitro Model of the Blood-Brain Barrier Cells. Journal of Biological Chemistry, 2008, 283, 34554-34562.	3.4	99
137	Insulin Facilitates the Hepatic Clearance of Plasma Amyloid β-Peptide (1–40) by Intracellular Translocation of Low-Density Lipoprotein Receptor-Related Protein 1 (LRP-1) to the Plasma Membrane in Hepatocytes. Molecular Pharmacology, 2007, 72, 850-855.	2.3	105
138	Correlation of Induction of ATP Binding Cassette Transporter A5 (ABCA5) and ABCB1 mRNAs with Differentiation State of Human Colon Tumor. Biological and Pharmaceutical Bulletin, 2007, 30, 1144-1146.	1.4	45
139	Function and regulation of taurine transport at the inner blood–retinal barrier. Microvascular Research, 2007, 73, 100-106.	2.5	65
140	Hyperammonemia induces transport of taurine and creatine and suppresses claudin-12 gene expression in brain capillary endothelial cells in vitro. Neurochemistry International, 2007, 50, 95-101.	3.8	53
141	Cerebral clearance of human amyloid-l̂² peptide (1–40) across the blood-brain barrier is reduced by complex formation of activated l̃±2-macroglobulin. Neuroscience Research, 2007, 58, S116.	1.9	1
142	Endothelial Cells Constituting Blood-nerve Barrier Have Highly Specialized Characteristics as Barrier-forming Cells. Cell Structure and Function, 2007, 32, 139-147.	1.1	44
143	Exogenous expression of claudin-5 induces barrier properties in cultured rat brain capillary endothelial cells. Journal of Cellular Physiology, 2007, 210, 81-86.	4.1	144
144	24S-hydroxycholesterol induces cholesterol release from choroid plexus epithelial cells in an apical- and apoE isoform-dependent manner concomitantly with the induction of ABCA1 and ABCG1 expression. Journal of Neurochemistry, 2007, 100, 968-978.	3.9	58

#	Article	IF	CITATIONS
145	Brainâ€toâ€blood elimination of 24Sâ€hydroxycholesterol from rat brain is mediated by organic anion transporting polypeptide 2 (oatp2) at the blood–brain barrier. Journal of Neurochemistry, 2007, 103, 1430-1438.	3.9	37
146	Cerebral clearance of human amyloidâ€Î² peptide (1–40) across the blood–brain barrier is reduced by selfâ€aggregation and formation of lowâ€density lipoprotein receptorâ€related proteinâ€1 ligand complexes. Journal of Neurochemistry, 2007, 103, 2482-2490.	3.9	75
147	Establishing a Method to Isolate Rat Brain Capillary Endothelial Cells by Magnetic Cell Sorting and Dominant mRNA Expression of Multidrug Resistance-associated Protein 1 and 4 in Highly Purified Rat Brain Capillary Endothelial Cells. Pharmaceutical Research, 2007, 24, 688-694.	3.5	32
148	Contribution of Carrier-Mediated Transport Systems to the Blood–Brain Barrier as a Supporting and Protecting Interface for the Brain; Importance for CNS Drug Discovery and Development. Pharmaceutical Research, 2007, 24, 1745-1758.	3.5	411
149	Multichannel Liquid Chromatography–Tandem Mass Spectrometry Cocktail Method for Comprehensive Substrate Characterization of Multidrug Resistance-Associated Protein 4 Transporter. Pharmaceutical Research, 2007, 24, 2281-2296.	3.5	62
150	A Novel Relationship Between Creatine Transport at the Blood-Brain and Blood-Retinal Barriers, Creatine Biosynthesis, And its Use for Brain and Retinal Energy Homeostasis., 2007, 46, 83-98.		35
151	Functional characterization of the brain-to-blood efflux clearance of human amyloid-β peptide (1–40) across the rat blood–brain barrier. Neuroscience Research, 2006, 56, 246-252.	1.9	113
152	Modulation and Compensation of the mRNA Expression of Energy Related Transporters in the Brain of Glucose Transporter 1-Deficient Mice. Biological and Pharmaceutical Bulletin, 2006, 29, 1587-1591.	1.4	28
153	ATP-Binding Cassette Transporter G2 Mediates the Efflux of Phototoxins on the Luminal Membrane of Retinal Capillary Endothelial Cells. Pharmaceutical Research, 2006, 23, 1235-1242.	3.5	69
154	Major Involvement of Low-Density Lipoprotein Receptor-Related Protein 1 in the Clearance of Plasma Free Amyloid \hat{I}^2 -Peptide by the Liver. Pharmaceutical Research, 2006, 23, 1407-1416.	3.5	100
155	Drug delivery system based on transport characteristics of biological membranes Molecular mechanisms of blood-brain barrier transport system and its contribution to drug delivery to the brain. Drug Delivery System, 2006, 21, 102-110.	0.0	0
156	Retinal-specific ATP-binding cassette transporter (ABCR/ABCA4) is expressed at the choroid plexus in rat brain. Journal of Neurochemistry, 2005, 92, 1277-1280.	3.9	27
157	Selective gene silencing of rat ATP-binding cassette G2 transporter in an in vitro blood-brain barrier model by short interfering RNA. Journal of Neurochemistry, 2005, 93, 63-71.	3.9	15
158	Distinct spatio-temporal expression of ABCA and ABCG transporters in the developing and adult mouse brain. Journal of Neurochemistry, 2005, 95, 294-304.	3.9	121
159	PKC/MAPK signaling suppression by retinal pericyte conditioned medium prevents retinal endothelial cell proliferation. Journal of Cellular Physiology, 2005, 203, 378-386.	4.1	16
160	Dominant expression of androgen receptors and their functional regulation of organic anion transporter 3 in rat brain capillary endothelial cells; Comparison of gene expression between the blood-brain and -retinal barriers. Journal of Cellular Physiology, 2005, 204, 896-900.	4.1	38
161	The Physiological Function of the Blood-Brain Barrier Transporters as the CNS Supporting and Protecting System. ChemInform, 2005, 36, no.	0.0	0
162	Vascular EndotheliumSelective Gene Induction by Tie2 Promoter/Enhancer in the Brain and Retina of a Transgenic Rat. Pharmaceutical Research, 2005, 22, 852-857.	3.5	17

#	Article	IF	Citations
163	Physiological pharmacokinetics and membrane transport for drug delivery research. International Congress Series, 2005, 1284, 266-273.	0.2	0
164	Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: An overview of biology and methodology. NeuroRx, 2005, 2, 63-72.	6.0	72
165	Brain-to-blood transporters for endogenous substrates and xenobiotics at the blood-brain barrier: An overview of biology and methodology. Neurotherapeutics, 2005, 2, 63-72.	4.4	0
166	Blood-Brain Barrier Permeability of Novel [d-Arg2]Dermorphin (1-4) Analogs: Transport Property Is Related to the Slow Onset of Antinociceptive Activity in the Central Nervous System. Journal of Pharmacology and Experimental Therapeutics, 2004, 310, 177-184.	2.5	18
167	Brain Insulin Impairs Amyloid- $\hat{A}(1-40)$ Clearance from the Brain. Journal of Neuroscience, 2004, 24, 9632-9637.	3.6	90
168	Mouse Reduced in Osteosclerosis Transporter Functions as an Organic Anion Transporter 3 and Is Localized at Abluminal Membrane of Blood-Brain Barrier. Journal of Pharmacology and Experimental Therapeutics, 2004, 309, 1273-1281.	2 . 5	74
169	Distinct cellular expressions of creatine synthetic enzyme GAMT and creatine kinases uCKâ€Mi and CKâ€B suggest a novel neuron–glial relationship for brain energy homeostasis. European Journal of Neuroscience, 2004, 20, 144-160.	2.6	149
170	A pericyteâ€derived angiopoietinâ€1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tieâ€2 activation ⟨i⟩in vitro⟨/i⟩. Journal of Neurochemistry, 2004, 89, 503-513.	3.9	299
171	Localization of organic anion transporting polypeptide 3 (oatp3) in mouse brain parenchymal and capillary endothelial cells. Journal of Neurochemistry, 2004, 90, 743-749.	3.9	54
172	Organic anion transporter 3 is involved in the brain-to-blood efflux transport of thiopurine nucleobase analogs. Journal of Neurochemistry, 2004, 90, 931-941.	3.9	80
173	Functional expression of rat ABCG2 on the luminal side of brain capillaries and its enhancement by astrocyte-derived soluble factor(s). Journal of Neurochemistry, 2004, 90, 526-536.	3.9	131
174	A new in vitro model for blood?cerebrospinal fluid barrier transport studies: an immortalized choroid plexus epithelial cell line derived from the tsA58 SV40 large T-antigen gene transgenic rat. Advanced Drug Delivery Reviews, 2004, 56, 1875-1885.	13.7	27
175	The l-isomer-selective transport of aspartic acid is mediated by ASCT2 at the blood-brain barrier. Journal of Neurochemistry, 2004, 87, 891-901.	3.9	57
176	mRNA Expression of the ATP-Binding Cassette Transporter Subfamily A (ABCA) in Rat and Human Brain Capillary Endothelial Cells. Biological and Pharmaceutical Bulletin, 2004, 27, 1437-1440.	1.4	34
177	New Aspects of the Blood-Brain Barrier Transporters; Its Physiological Roles in the Central Nervous System. Biological and Pharmaceutical Bulletin, 2004, 27, 1489-1496.	1.4	84
178	Transporter mRNA Expression in a Conditionally Immortalized Rat Small Intestine Epithelial Cell Line (TR-SIE). Drug Metabolism and Pharmacokinetics, 2004, 19, 264-269.	2.2	9
179	Retinal selectivity of gene expression in rat retinal versus brain capillary endothelial cell lines by differential display analysis. Molecular Vision, 2004, 10, 537-43.	1.1	9
180	New approaches to in vitro models of blood–brain barrier drug transport. Drug Discovery Today, 2003, 8, 944-954.	6.4	158

#	Article	IF	Citations
181	Expression and regulation of L-cystine transporter, system xc?, in the newly developed rat retinal M�lelr cell line (TR-MUL). Glia, 2003, 43, 208-217.	4.9	85
182	Blood-brain barrier transport of a novel $\hat{A}\mu 1$ -specific opioid peptide, H-Tyr-d-Arg-Phe- \hat{I}^2 -Ala-OH (TAPA). Journal of Neurochemistry, 2003, 84, 1154-1161.	3.9	35
183	Rat Organic Anion Transporter 3 (rOAT3) is Responsible for Brain-to-Blood Efflux of Homovanillic Acid at the Abluminal Membrane of Brain Capillary Endothelial Cells. Journal of Cerebral Blood Flow and Metabolism, 2003, 23, 432-440.	4.3	151
184	In Vitro Study of the Functional Expression of Organic Anion Transporting Polypeptide 3 at Rat Choroid Plexus Epithelial Cells and Its Involvement in the Cerebrospinal Fluid-to-Blood Transport of Estrone-3-Sulfate. Molecular Pharmacology, 2003, 63, 532-537.	2.3	63
185	Establishment of Conditionally Immortalized Rat Retinal Pericyte Cell Lines (TR-rPCT) and Their Application in a Co-culture System Using Retinal Capillary Endothelial Cell Line (TR-iBRB2). Cell Structure and Function, 2003, 28, 145-153.	1.1	39
186	Rat Organic Anion Transporter 3 (rOAT3) Is Responsible for Brain-to-Blood Efflux of Homovanillic Acid at the Abluminal Membrane of Brain Capillary Endothelial Cells. Journal of Cerebral Blood Flow and Metabolism, 2003, , 432-440.	4.3	64
187	New in vitro model for the brain drug delivery research: Conditionally immortalized cell lines as novel models of the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCSFB). Drug Delivery System, 2003, 18, 118-125.	0.0	0
188	ATA2 Is Predominantly Expressed as System A at the Blood-Brain Barrier and Acts as Brain-to-Blood Efflux Transport forl-Proline. Molecular Pharmacology, 2002, 61, 1289-1296.	2.3	71
189	Enhancement of I-Cystine Transport Activity and Its Relation to xCT Gene Induction at the Blood-Brain Barrier by Diethyl Maleate Treatment. Journal of Pharmacology and Experimental Therapeutics, 2002, 302, 225-231.	2.5	55
190	mRNA Expression and Amino Acid Transport Characteristics of Cultured Human Brain Microvascular Endothelial Cells (hBME). Drug Metabolism and Pharmacokinetics, 2002, 17, 367-373.	2.2	23
191	Localization of norepinephrine and serotonin transporter in mouse brain capillary endothelial cells. Neuroscience Research, 2002, 44, 173-180.	1.9	76
192	Blood-Brain Barrier Is Involved in the Efflux Transport of a Neuroactive Steroid, Dehydroepiandrosterone Sulfate, via Organic Anion Transporting Polypeptide 2. Journal of Neurochemistry, 2002, 75, 1907-1916.	3.9	127
193	Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. Journal of Neurochemistry, 2002, 83, 57-66.	3.9	196
194	Internalization of basic fibroblast growth factor at the mouse blood-brain barrier involves perlecan, a heparan sulfate proteoglycan. Journal of Neurochemistry, 2002, 83, 381-389.	3.9	62
195	Regulation of taurine transport at the blood-brain barrier by tumor necrosis factor- \hat{l} ±, taurine and hypertonicity. Journal of Neurochemistry, 2002, 83, 1188-1195.	3.9	105
196	Major role of organic anion transporter 3 in the transport of indoxyl sulfate in the kidney. Kidney International, 2002, 61, 1760-1768.	5.2	128
197	Recent advances in the brain-to-blood efflux transport across the blood–brain barrier. International Journal of Pharmaceutics, 2002, 248, 15-29.	5 . 2	42
198	The Blood–Brain Barrier Creatine Transporter is a Major Pathway for Supplying Creatine to the Brain. Journal of Cerebral Blood Flow and Metabolism, 2002, 22, 1327-1335.	4.3	161

#	Article	IF	Citations
199	The Blood???Brain Barrier Creatine Transporter Is a Major Pathway for Supplying Creatine to the Brain. Journal of Cerebral Blood Flow and Metabolism, 2002, , 1327-1335.	4.3	60
200	Blood-Brain Barrier Transport and Drug Targeting to the Brain. , 2002, , 313-326.		0
201	Induction of xCT gene expression and L-cystine transport activity by diethyl maleate at the inner blood-retinal barrier. Investigative Ophthalmology and Visual Science, 2002, 43, 774-9.	3.3	39
202	Conditionally Immortalized Retinal Capillary Endothelial Cell Lines (TR-iBRB) Expressing Differentiated Endothelial Cell Functions Derived from a Transgenic Rat. Experimental Eye Research, 2001, 72, 163-172.	2.6	147
203	Acidic Amino Acid Transport Characteristics of a Newly Developed Conditionally Immortalized Rat Type 2 Astrocyte Cell Line (TR-AST) Cell Structure and Function, 2001, 26, 197-203.	1.1	29
204	Characterization of the amino acid transport of new immortalized choroid plexus epithelial cell lines: a novel in vitro system for investigating transport functions at the blood-cerebrospinal fluid barrier. Pharmaceutical Research, 2001, 18, 16-22.	3.5	61
205	MCT1-mediated transport of L-lactic acid at the inner blood-retinal barrier: a possible route for delivery of monocarboxylic acid drugs to the retina. Pharmaceutical Research, 2001, 18, 1669-1676.	3.5	99
206	GAT2/BGT-1 as a System Responsible for the Transport of γ-Aminobutyric Acid at the Mouse Blood–Brain Barrier. Journal of Cerebral Blood Flow and Metabolism, 2001, 21, 1232-1239.	4.3	150
207	Conditionally immortalized brain capillary endothelial cell lines established from a transgenic mouse harboring temperature-sensitive simian virus 40 large T-antigen gene. AAPS PharmSci, 2000, 2, 69-79.	1.3	63
208	mRNA Expression and Transport Characterization of Conditionally Immortalized Rat Brain Capillary Endothelial Cell Lines; a New <i>in vitro</i> BBB Model for Drug Targeting. Journal of Drug Targeting, 2000, 8, 357-370.	4.4	102
209	GAGA mediates the enhancer blocking activity of the <i>eve</i> promoter in the <i>Drosophila</i> embryo. Genes and Development, 1998, 12, 3325-3330.	5.9	145
210	cDNA Cloning of Mouse Prolyl Endopeptidase and Its Involvement in DNA Synthesis by Swiss 3T3 Cells. Journal of Biochemistry, 1998, 123, 540-545.	1.7	40
211	Different core promoters possess distinct regulatory activities in the Drosophila embryo. Genes and Development, 1998, 12, 547-556.	5.9	193
212	Nuclear Localization and Involvement in DNA Synthesis of Sarcophaga Prolyl Endopeptidase. Journal of Biochemistry, 1997, 121, 1176-1181.	1.7	21
213	Molecular cloning of cDNA for Sarcophaga prolyl endopeptidase and characterization of the recombinant enzyme produced by an E. coli expression system. Insect Biochemistry and Molecular Biology, 1997, 27, 337-343.	2.7	11
214	A Prolyl Endopeptidase of Sarcophaga peregrina (Flesh Fly): Its Purification and Suggestion for Its Participation in the Differentiation of the Imaginal Discs1. Journal of Biochemistry, 1994, 115, 449-453.	1.7	46
215	Human Immortalized Cell-Based Blood–Brain Barrier Spheroid Models Offer an Evaluation Tool for the Brain Penetration Properties of Macromolecules. Molecular Pharmaceutics, 0, , .	4.6	3